Skip to main content

Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response



Cantharidin (CTD) is a major ingredient of cantharis (Mylabris phalerata Pallas) and has been used extensively in traditional Chinese medicines. It has been shown to exhibit anticancer activity in multiple types of cancer, especially hepatocellular carcinoma (HCC). However, there is no systematic study on the relationships among the regulatory networks of its targets in HCC therapy. We focused on histone epigenetic regulation and the influence of CTD on the immune response in HCC.


We performed a comprehensive analysis of novel CTD targets in HCC based on network pharmacology and RNA-seq approaches. The mRNA levels of target genes were analyzed by qRT-PCR, and the corresponding protein levels were confirmed using enzyme-linked immunosorbent assay (ELISA) and immunohistochemical staining (IHC). ChIP-seq data were visualized by IGV software. The associations of gene transcript levels with the cancer immune score and infiltration level were investigated using TIMER. In vivo, the H22 mouse model of hepatocellular carcinoma was established by treatment with CTD and 5-Fu. The immune cell proportions in the blood were elevated in model mice, as shown by flow cytometry.


We identified 58 targets of CTD, which were involved in various pathways in cancer, including apoptosis, the cell cycle, EMT and immune pathways. Moreover, we found that 100 EMT-related genes were differentially expressed after CTD treatment in HCC cells. Interestingly, our results confirmed that the EZH2/H3K27me3 -related cell cycle pathway is a therapeutic target of CTD in antitumour. In addition, we evaluated the influence of CTD on the immune response. Our data showed that the significantly enriched gene sets were positively correlated with the chemokine biosynthetic and chemokine metabolic modules. The proportions of CD4+/CD8 + T cells and B cells were increased, but the proportion of Tregs was decreased after treatment with CTD in vivo. Moreover, we found that the expression of the inflammatory factor and immune checkpoint genes PD­1/PD-L1 was significantly reduced in the mouse model.


We performed a novel integrated analysis of the potential role of CTD in HCC treatment. Our results provide innovative insight into the mechanism by which cantharidin exerts antitumour effects by regulating target genes expression to mediate apoptosis, EMT, cell cycle progression and the immune response in HCC. Based on the effect of CTD on the immune response, it can be used as a potential effective drug to activate antitumour immunity for the treatment of liver cancer.

Peer Review reports


Hepatocellular carcinoma (HCC) is one of the most common malignant tumours with a high rate of recurrence and mortality worldwide [1, 2]. At present, the survival of patients with advanced HCC remains intractably low due to the latency period and insensitivity to chemotherapy [3]. In recent years, more and more studies have indicated that Chinese herbal medicines have obvious benefits in the treatment of solid tumours, including HCC [4, 5]. Therefore, exploring the molecular mechanisms of these medicines will provide more precise direction for the treatment of liver cancer.

Cantharidin is a sesquiterpenoid bioactive substance extracted from cantharis (Mylabris phalerata Pallas), which is a traditional Chinese medicinal preparation. The chemical formula of cantharidin is C10H12O4, and the chemical structure is shown in Supplementary Figure S1. Cantharidin and related pharmaceutical preparations have been reported to have anticancer activity [6,7,8]. For example, CTD is a major ingredient of Aidi injection (China Food and Drug Administration Z52020236) [7], which is approved for clinical use in China in 2002 [6, 7], and is widely used for the treatment of several cancer types, including liver cancer [7, 8], lung cancer [9], colorectal cancer [8], and gastric carcinoma [10].

Numerous studies have proposed mechanisms by which cantharidin exhibits antitumour activity by affecting the synthesis of RNA and DNA to induce DNA damage and apoptosis, and suppress cell proliferation in several types of tumours [11]. Several studies have indicated that CTD treatment suppresses cell proliferation via JAK2/STAT3, PI3K/Akt, and p38 MAPK pathway regulation [12,13,14]. Moreover, CTD can function as an inhibitor of protein phosphatase 2 A (PP2A) to induce DNA damage and apoptosis [15]. Recently, it has been reported that CTD could increase the chemosensitivity of liver cancer cells to upregulate the expression of KDM4A and lead to H3K36me3-dependent DNA damage in HCC [16]. However, new therapeutic targets and detailed pharmacological mechanisms remain to be further elucidated. In our study, integrated analysis of the pharmacological mechanism of cantharidin, its epigenetic regulation, especially H3K27me3-related histone modification, and its effects on the immune response pathway were performed to determine its utility for the treatment of HCC.

Histone methylation plays a crucial role in regulating chromatin formation and gene expression to affect pathological processes in various cancers [17,18,19]. Enhancer of Zeste Homolog 2 (EZH2) is a core component of Polycomb Repressive Complex 2 (PRC2), which has been reported to play important role in oncogenesis, tumour growth and metastasis in numerous malignant tumours by regulating gene expression through trimethylation of H3K27 [17]. EZH2 could be a potential therapeutic target in HCC. Moreover, it has been confirmed that EZH2 can regulate the expression of inflammatory cytokines and chemokines [18, 19].

We performed a comprehensive integrated analysis of the pharmacology and molecular mechanisms of cantharidin in HCC. In particular, we identified new potential targets of CTD and mainly focused on EZH2-H3K27me3-related gene expression networks in the context of HCC therapy. Moreover, we investigated the association of cantharidin with aspects of the immune response, especially chemokine-, inflammatory factor- and immune checkpoint gene-related pathways. Our findings provide new insight into the mechanism of cantharidin in antitumour therapy for HCC.

Materials and methods

Pharmacological regulatory network analysis

CTD-related targets were assessed based on data from drug target prediction platforms, including the Herb, SWISS-PROT, and Stitch databases. Then, the PPI network of CTD and its targets was constructed via Cytoscape 3.2.1 software. Moreover, we used the Venn diagram package to confirm the key targets, key module genes, drug targets, and disease targets of HCC based on the differentially expressed gene sets after CTD treatment in HCC cells and information about CTD targets obtained from databases. The hub gene set was obtained based on a bioinformatics approach [20, 21] Furthermore, the involvement of these genes in functions and pathways were confirmed based on Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) [22, 23].

Reagents and cells

Cantharidin was purchased from Sigma-Aldrich, China (C7632, purity ≥ 98%). H22 cell was obtained from the Cell Bank of Chinese Academy of Sciences. 5-FU was purchased from Solarbio, China.

RNA-seq analysis

Total RNA was obtained by the TRIzol method according to the manufacturer’s instructions. RNA-seq was performed by the HiSeqTM 2500 system (Illumina) at Novogene Corporation Inc. The difference in the expression matrix based on the sequencing data was analysed using the R package. Genes with a mean signal |logFC| ≥1, and P value ≤ 0.05 were considered to be significantly differentially expressed genes (DEGs) for further analysis. All the differentially expressed genes are listed in the Additional file 1. Functional and pathway enrichment analyse were performed based on GO terms, KEGG pathways and gene set enrichment analysis (GSEA). GSEA hallmark gene sets were obtained from MSigDB.

ChIP-seq data analysis

The H3K27me3 ChIP-seq data of HepG2 cells were obtained from the Cistrome DB database. The Venn diagram package was used to identify the key genes based on a bioinformatics approach [24, 25]. The overlap of the H3K27me3 ChIP and RNA-seq data was confirmed. The levels of H3K27me3 enrichment in gene promoter regions were visualized by IGV2.13.2 software.

Correlation analysis of immune checkpoints

Immune analysis of CXC and CCL chemokines in LIHC was performed using the ESTIMATE algorithm. The correlations between chemokine levels and immune cell infiltration, the immune score and the stromal score were assessed by Spearman correlation analysis. A p-value < 0.05 was considered significance threshold.

Immune infiltration analysis

The correlations between chemokine levels and the infiltration of the 25 immune cell types were evaluated in LIHC based on the GSCA (Gene Set Cancer Analysis) database. The GSVA package was used to analyse the levels of immune cell infiltration in the groups with threshold criteria of a false discovery rate (FDR) < 0.05 and p value < 0.05. A p-value of < 0.05 was considered significance threshold.

Establishment of the animal model and in vivo experiment

The H22 mouse model of hepatocellular carcinoma was constructed to confirm the antitumour function of cantharidin in vivo. The Male BALB/c mice (5–6 weeks old) weighing 20 ± 2 g was purchased from Beijing Viton Lihua Experimental Animal Technology Co., LTD. We randomly divided the H22 tumour-bearing mice into five groups (n = 10 per group): the control (oral administration of saline solution), groups treated with different doses of CTD (low (0.25 mg/kg), middle (0.5 mg/kg) and high (1 mg/kg)), and a group treated with 5-Fu (0.5 ml). CTD was obtained from Sigma-Aldrich, and its purity was ≥ 98.0%. The mice were weighed every 2 days. After two weeks, all the mice were fasted for 12 h, anesthetized by administration with 10% ULTANE per 10 g/ml intraperitoneal injection (Beijing Bailingwei Technology Co., LtD.) and sacrificed by cervical dislocation. The tumours were obtained and weighed before washing in normal saline. The inhibition rate (%) of tumour was calculated (mean tumor weight of model group - mean tumour weight of treatment group)/mean tumour weight of model group × 100%) and recorded.

Haematoxylin and eosin (H&E) staining

The tumour tissues were fixed with 4% paraformaldehyde, dehydrated with 75% ethanol and embedded in paraffin. The samples were cut into 4 μm-thick sections and dewaxed with xylene. Then, they were rehydrated in an ethanol gradient and stained using haematoxylin. Next, the samples were immersed first in hydrochloric acid alcohol differentiation solution and then in eosin solution. Next, the sections were observed and photographed using a microscope.

Analysis of immune cells in blood by flow cytometry

Blood samples (100 µL) were collected from mice in each group 20 days after drug treatment. Then, the red blood cells were lysed by ACK lysing buffer (Solarbio, China). Flow cytometry was used to confirm the percentages of CD4 + T (CD3 + CD4+), CD8 + T (CD3 + CD8), B (CD19+), and Treg (CD25+) cells in peripheral blood (Beckman, USA). Treg cells were detected from the CD4 + T cell population. The CD25 + phenotype represented Treg cells. Monocytes in peripheral blood were used as the total analysis population, and the CD19 + phenotype represented B cells. All the data were analysed using FlowJo7.6 software.

Enzyme-linked immunosorbent assay (ELISA)

Tissue (5 mg) was collected, and PBS buffer was added. Then the tissue homogenate was prepared by a homogenizer. The concentrations of IL-2, IL-4, IL-10, TNF-α, and IFN-γ were determined by ELISA kits (Bio Legend, USA) according to the manufacturer’s instructions. The concentrations of IL-2, IL-4, IL-10, TNF-α, and IFN-γ were calculated using a microplate reader (Bio-Rad, Italy). A P value of < 0.05 was regarded as statistically significant, * p < 0.05.

Immunohistochemical staining (IHC)

The expression of PD1 and PDL1 was confirmed using an IHC assay. Sections were obtained and incubated first with anti-PD1 and anti-PDL1 antibody for 16 h at 4 °C and then with a secondary antibody for 2 h at room temperature. Then, the secondary antibody was detected using a Tissue Staining Horseradish Peroxidase (HRP)-Diaminobenzidine (DAB) Kit. In addition, the protein expression levels of CCNA2, CENPA, BRCA2, RFC3, PSME3, and TERF2 in patients with HCC were obtained from the HPA database.

Real-time RT-PCR

Total RNA was extracted using RNA Plus Reagent (Takara, China) and reverse transcribed into cDNA using a PrimeScript RT Reagent Kit (Takara, China). A SYBR Premix Ex Taq II (Takara, China) Kit was used to measure the mRNA level of each gene. The assay was performed in the CFX6 thermal cycler (Bio Rad, USA). Target genes expression were normalized to GAPDH expression to evaluate their expressions. All experiments were repeated more than three times. The results were considered to be statistically significant when the value of p was < 0.05, * p < 0.05, ** p < 0.01.

Statistical analysis

Data are summarized as the mean ± standard deviation (SD) values. Student’s t test was used to analysed the differences between two groups, while one-way ANOVA followed by the Tukey’s post-hoc test was performed to evaluate the statistical significance among multiple groups. Differences were considered to be statistically significant when the value of p was < 0.05.


Prediction and enrichment analysis of potential therapeutic targets and pathways of cantharidin in HCC

To dertermine the pharmacological mechanism of cantharidin in HCC, the targets of cantharidin were obtained from the Herb, Stitch, and SWISS-PROT databases, and the network pharmacology map was constructed based on the interactions between these targets and LIHC (Fig. 1A). Moreover, protein function annotation indicated that these targets of CTD were mainly enzymes, phosphatases, kinases, and oxidoreductases (Fig. 1B). To further explore the therapeutic targets of CTD in HCC, the HepG2 cells were treated with cantharidin and subjected to RNA-seq analysis. Subsequently, integrated analysis was performed based on the RNA-seq results and database information. A Venn diagram was used to confirm the key targets of CTD based on the targets predicted by the databases and the differentially expressed genes (DEGs) identified by RNA-seq in HCC (Fig. 1C). In total, 58 DEGs overlapped with targets from the databases, suggesting that these genes are the key targets of CTD in HCC (Fig. 1D). Furthermore, the interaction network of these target proteins was constructed via the STRING database. As shown in Fig. 1E, MAPK8/9/10/11/14, the PP1 and PP2 phosphatases, NFKB1A, and EGFR were the hub targets of CTD (Fig. 1E). Additionally, the KEGG enrichment analysis results indicated that these genes were significantly enriched in pathways in cancer. Moreover, these genes were also involved in the TNF signalling pathway, the MAPK signalling pathway, inflammatory mediator regulation of TRP channels, the IL-17 signaling pathway, the T cell receptor signaling pathway, and the apoptosis pathway (Fig. 1F). Considering these results collectively we speculated that cantharidin exerts its therapeutic effect by regulating these target genes and their related signalling pathways to inhibit the development of liver cancer.

Fig. 1
figure 1

The targets network of cantharidin in HCC. (A) Network diagram of pharmacological regulation of cantharidin targets in HCC. Purple represents the targets of cantharidin from Herb database, dark green shows the targets of cantharidin from Sitch database; green and yellow are the targets from Swiss database. The probability yellow marker gene > 0.03, green marker gene < 0.03. (B) Statistical analysis protein properties of targets from different database. (C) The venn diagram shows the intersection of targets gene sets from three database and differentially expressed genes from cantharidin treated HepG2 cell. (D) Heat map shows the gene expression of predicted cantharidin targets in HepG2 cell. (E) PPI network of cantharidin targets in HCC. Red and green represent two hub networks in cantharidin targets. (F) Pathways with significant enrichment of target genes of cantharidin in HCC

To further explore the potential mechanism of cantharidin in HCC, we analysed our transcriptome data in depth. Based on threshold value of p < 0.05 and |log2FoldChange| > 1, a total of 7008 upregulated genes and 2427 downregulated genes were identified between HepG2 cells with and without cantharidin treatment (Fig. 2A). The expression of these genes was shown in Fig. 2B. Subsequently, GO and KEGG enrichment analyses were performed. These DEGs were significantly enriched in the terms of epithelium migration, epithelial cell migration, and tissue migration (Fig. 2C), suggesting that cantharidin likely inhibits cell metastasis by regulating EMT in liver cancer. Furthermore, the EMT gene set was obtained from the GSEA database and we found that 100 EMT-related genes were differently expressed after CTD treatment (Fig. 2D). Then, a PPI network of EMT-related genes was constructed according to the interaction relationships in the STRING database (Fig. 2E). The results indicated that cantharidin likely regulates these EMT-related genes to inhibit tumour cell growth and metastasis. Next, KEGG enrichment analysis was performed, and the results showed that the top 4 terms were “Cytokine-cytokine receptor interaction”, “ECM-receptor interaction”, “Transcription mis-regulation in cancer” and “Pathways in cancer” (Fig. 2F). Moreover, the top 10 cancer-related pathways were showed in Fig. 2G, including the MAPK, PI3K-Akt, cAMP, Jak-STAT, Wnt, NF-kappa B, AMPK and HIF-1 signalling pathways. Taken together, these finding indicate that CTD might inhibit HCC cell growth by regulating the above multiple pathways.

Fig. 2
figure 2

Differentially expressed genes and their function enrichment analysis in cantharidin treated HepG2 cell. (A, B) volcano plot and heat map visualization of the differentially expressed genes after cantharidin treatments in HepG2. Red represents upregulation genes; green represents downregulation genes. (A) Volcano plot of genes. (B) Heat map of differentially expressed genes that logFC > 1, <-1, p < 0.05. (C) GO enrichment of differentially expressed genes. (D) The EMT related genes after cantharidin treatment HepG2 cell was screened using venn diagram. (E) PPI network of EMT related genes. (F) KEGG enrichment of the differentially expressed genes after cantharidin treatment in HepG2 cell. (G) Top 10 significantly enriched signaling pathways in cantharidin treated HepG2 cell

EZH2/H3K27me3 is essential for cell cycle progression in cantharidin treated HCC cells

Gene set enrichment analysis was performed to find promising therapeutic targets specific for CTD. Interestingly, the results showed that the DEGs in the CTD treated group were positively associated with H3K27me3 (Fig. 3A). EZH2 was significantly upregulated in CTD-treated samples compared to non-CTD-treated samples, implying that EZH2 may be the reason for the increase of H3K27me3 level after CTD treatment (Fig. 3B). Moreover, the RT-PCR results confirmed that EZH2 was upregulated in CTD treated HepG2 cells (Fig. 3C). To confirm the CTD-related H3K27me3-modified and repressed genes, we integrated our RNA-seq data from HepG2 cells and ChIP-seq datasets from the Cistrome Data Browser database. In total, 97 genes were occupied and downregulated by H3K27me3 in HepG2 cells (Fig. 3D, E). These data revealed that EZH2/H3K27me3 involved downstream target gene expression might play a critical role in the antitumour therapeutic effects of CTD.

Fig. 3
figure 3

Cantharidin treatment is involved in EZH2/H3K27me3 related cell cycle pathway regulation. (A) GO functional annotation shows that cantharidin treatment is positively associated with H3K27me3 pathway based on GSEA analysis. (B) The heatmap shows H3K27me3 related genes expression in cantharidin treated HepG2 cell. Red represents up-regulation genes; blue represents down-regulation genes. (C) The expression of PRC2 complex genes, the key regulatory enzyme of H3K27me3, in cantharidin treated HepG2 cell. The *P < 0.05 was regarded as statistically significant. (D) Venn diagram shows the target genes of cantharidin downregulation genes and H3K27me3 significantly enriched genes from ChIP-seq results in HepG2 cell. (E) The heatmap shows the expression of 97 genes from venn analysis, which may be target genes of H3K27me3 in cantharidin treatment. Red represents up-regulation genes, green represents down-regulation genes. (F) Go enrichment analysis of the predicted target gene set. (G) Pathway analysis of the predicted target gene set. (H) PPI network of these target genes based on the STRING database results

We next uploaded the target genes to Metascape and found that these genes were significantly enriched in the regulation of organelle biogenesis and maintenance, mitochondrial translation, and cell cycle (Fig. 3F). Moreover, these genes were associated with cell cycle related pathways, such as mtorc1 signalling, mitotic spindle, E2F targets, and G2M checkpoint (Fig. 3G). To further confirm the relationships between these genes and EZH2, we constructed a PPI regulation network. The PPI results indicated that 7 proteins, DY310, FBXL19, CENPA, KAT8, CCNA2, NRAS, and CALR, directly interact with EZH2 (Fig. 3H). This information supported the notion that EZH2/H3K27me3 might directly suppress these genes to regulate the cell cycle during CTD therapy for liver cancer.

Prediction of H3K27me3-related potential therapeutic targets of cantharidin in HCC

We further searched disease targets of HCC and retrieved 5875 targets in the disease target database. The Venn diagram showed 22 co-target genes between the cantharidin/H3K27me3-related targets in HepG2 cells and the targets of liver cancer (Fig. 4A). Among them, CCNA2, CENPA, CPE, BRCA2, RFC3, B9D1, RPGR1P1L, NF2, and PSME3 exhibited significantly elevated expression (fold change > 1.5) in the tissues of patients with HCC compared with the normal tissues (Fig. 4B). Moreover, their protein levels were also increased in the tissues of patients with HCC (Fig. 4C). Among of them, CCNA2, CENPA, BRCA2, RFC3, PSME3, ENSA and TERF2 were significantly decreased (log2FC<-1) in CTD treated HCC cells (Fig. 4D). Moreover, the ChIP-seq results showed that H3K27me3 could be enriched in the promoter regions of these dramatically downregulated genes (Fig. 4E). Thus, we hypothesized that the EZH2/H3K27me3 cascade acts as a therapeutic target of CTD-related liver cancer treatment.

Fig. 4
figure 4

H3K27me3 related cantharidin treatment target prediction analysis in HCC. (A) Venn diagram shows the genes of liver carcinoma and H3K27me3 related cantharidin treatment targets. (B) The expression of these targets in LIHC. Red represents high expression; blue represents low expression. P < 0.05 is considered significant. (C) Proteins expression of significantly up-regulated genes in LIHC. (D) These genes expression in cantharidin treated HepG2 cell. The * P < 0.05 was regarded as statistically significant. (E) H3K27me3 is dramatically enriched in these genes promoters based on the ChIP-seq results in HepG2

Cantharidin regulated chemokine-related gene expression in liver cancer cells

Further GSEA analysis was performed on the overall expression data of CTD-related genes. The significantly enriched gene sets that positively correlated with CTD were the chemokine biosynthetic and chemokine metabolic modules (Fig. 5A, B). Then, we obtained chemokine- and chemokine receptor-related genes from the GSEA database. The Venn diagram shows that 36 chemokines and 22 chemokine receptors were differentially expressed in cantharidin-treated HepG2 cells (Fig. 5C). Notably, we found that CXCL1/2/3/8 and CCL20/21/24/26 were significantly upregulated, but SEMA3/4/6 were downregulated after CTD treatment (Fig. 5D). Additionally, the levels of CX3CR1, CXCR1, CCRL2, CCR7, CXCR4 and other chemokine receptors with atypical structures were increased and those of five members of the PLXN chemokine receptor family were dramatically decreased in the CTD treatment group (Fig. 5E). Furthermore, the correlations of EZH2 and chemokine were evaluated in HCC. As shown in Fig. 5F, EZH2 expression was significantly associated with that of several chemokines and chemokine receptors, including CXCL6, CCL7, CCL8, CCL22, CXCL10, CCL27, CCL18, CCL16, CXCR4, CCR8, CCR10, CCR1, and CCR7, in HCC.

Fig. 5
figure 5

The cantharidin treatment affects chemokine related immune response. (A, B) GO functional annotation shows that cantharidin treatment is positively associated with chemokine biosynthetic and metabolic processes based on GSEA analysis. (C) Venn diagram shows that the differently expressed genes of chemokine and chemokine receptor in the cantharidin treated HepG2 cell. (D, E) The heatmap shows the expression of chemokine (D), and chemokine receptor (E) in the differently expressed genes of cantharidin treated HepG2 cell. (F) The heatmap shows the association of chemokine and chemokine receptor with EZH2 in LIHC, * P < 0.05 was regarded as statistically significant

In addition, the expression of CXC and CCL chemokines involved in the immune response was elevated. We found that the levels of the CTD-related chemokines CXCL1/2/3/8 and CCL20/21/24/26 were significantly correlated with the stromal score and immune score (Fig. 6A, B). Moreover, the relationships between differentially expressed chemokines and immune cell infiltration were evaluated in LIHC. Most chemokines and chemokine receptor were positively associated with immune cells infiltration, including CD4 + cells, NK cells, macrophages, and Treg cells (Fig. 6C, D). Among these genes, the chemokines SEMA4A, SEMA4D, CCL13, and CCL21 and the chemokine receptors C5AR1, PLAUR, CCRL2, FPR2, PTAFR, CCR7 and CXCR4 may be critical genes for immune cell infiltration (Cor > 0.48). Integrated analysis with the transcriptome data indicated that CTD-related DEGs were associated with several immune response signalling pathways, such as MAPK, PI3K-AKT, NF-kappa B, and HIF-1α pathways. Therefore, CTD likely inhibits the progression of HCC by affecting chemokines involved immune cell trafficking and immune signalling responses.

Fig. 6
figure 6

Cantharidin related chemokines were involved in tumor immune. (A, B) The correlations between CXC (A) and CCL (B) chemokines and immune score, stromal score, and ESTIMATE score. (C, D) The correlations between the expression of cantharidin related chemokines (C), chemokine receptors (D) and the immune infiltration levels of 25 immune cells, which were analyzed by using the GSCA tools. Purple represents a positive correlation; green represents a positive correlation. * P < 0.05 and # FDR < 0.05 were regarded as statistically significant

Cantharidin inhibits tumour growth and enhances antitumour immunity in vivo

To further confirm the antitumour function of CTD in HCC, we investigated the effect of CTD on tumour growth in vivo. The results showed that tumour volume and weight were significantly decreased in mice treated with a high concentration of CTD and 5-FU (Fig. 7A, B). The tumour inhibition rate of CTD was similar to that of 5-FU (Fig. 7B). However, the CTD group did not exhibit significantly altered total body weight compared with the 5-FU group (Fig. 7C). Moreover, the HE staining results showed that the number of cells was dramatically reduced and that the cell were loosely arranged. The numbers of necrotic and apoptotic cells were increased in the CTD group. As observed the 5-FU group, the number of abnormal vacuoles was increased in the high-concentration CTD group (Fig. 7D). Therefore, CTD could reduce tumour cell growth and promote apoptosis in vivo.

Fig. 7
figure 7

The cantharidin improves antitumor immunity in mice. (A) Cantharidin represses the tumor cell growth in vivo.(B) Statistics of the tumor volume, weight, and inhibition rate in mice after therapy with cantharidin and 5-FU. Cantharidin and 5-FU have similar inhibitory effects on tumor growth. Data are presented as the mean ± SD (n = 3), * P < 0.05, ** P < 0.01 vs. the control group. (C) The mice body weight of different model groups. (D) The H&E staining of tumor tissues, including model, 5-FU, CTD high, middle, and low groups. (E-I) Proportion of CD4+ (E), CD8+ (F), Treg (G), and B cell (H) in mice after therapy with cantharidin. To detect the immune cells, blood samples are collected from each treatment group. Cells are stained with anti-CD4, anti‐CD8, anti-CD25, and anti-CD19 antibodies and analyzed by flow cytometry. (I) Statistics of the frequency CD4+, CD8+, Treg, and B cell in mice blood. (J) Elisa assay confirms the expression of immune related genes, IL-2, IL-4, IL-10, TNF-γ, and TNF-α. (K) RT-PCR analyses the expression of PD1 and PD-L1 in the tumor tissues. The * P < 0.05, ** P < 0.01. P value of < 0.05 was regarded as statistically significant. (L) Immunohistochemistry and quantitative analyses the expression of PD1 and PD-L1 in the tumor tissues after therapy with cantharidin

In addition, the CTD-mediated immune response was assessed. Flow cytometry was used to determine the proportions of CD4 + cells, CD8 + cells, Tregs and B cells in the blood of mice (Fig. 7E-H). The results showed that the proportions of CD4+/CD8 + T and B cells were increased after treatment with CTD, while the frequency of Tregs was decreased in the CTD group (Fig. 7I). These results indicated that CTD could inhibit tumour growth by affecting the immune cell distribution to enhance the antitumour immune response in HCC. We then proceeded to further investigate the molecular mechanism of CTD in the immune response. We measured the levels of inflammatory cytokines (TNF-α, IFN-γ, IL-2, IL-4, and IL-10) in the peripheral blood of model mice. As shown in Fig. 7J, IL-2, IL-4, and IFN-γ were elevated, but TNF-α and IL-10 were decreased following treatment with CTD. Next, the expression levels of the immune checkpoint genes PD­1/PD-L1 was were confirmed to investigate the effect of CTD on the immune response. The mRNA and protein expression levels of PD­1/PD-L1 were significantly reduced after CTD treatment (Fig. 7K, L). Therefore, it can be preliminarily concluded that CTD plays a critical role in the regulation of the immune response in exerting its anti-tumorigenic effects.


Cantharidin is the major component of the anticancer medicine obtained from cantharis and exhibits antitumour activity in several cancers, especially HCC [11]. Cantharidin and its derivatives are used in clinical antitumour therapy [26, 27]. However, the application of cantharidin is very limited due to its considerable hepatotoxicity. Recently, an increasing number of cantharidin derivative-related drugs have been developed, such as norcantharidin, magnesium demethylcantharidate, and methyl-cantharidimide [28,29,30], which exhibit lower toxicity and retain their anticancer activity. Norcantharidin has been reported to suppress c-Met-mTOR signalling to induce cell death in HCC [31]. The combination of magnesium demethylcantharidate and sorafenib results in FOXO1 activation to inhibit cell invasion and metastasis [29]. Methyl-cantharidimide plays a critical role in reducing cisplatin resistance at ABCB1- and ABCG2-overexpressing cancer cells [32]. Therefore, a comprehensive analysis of the pharmacodynamic targets of cantharidin and its molecular mechanism is necessary for the application of cantharidin antitumour therapy in HCC.

In this study, we comprehensively analysed the potential pharmacodynamic targets of cantharidin in HCC. In total, 58 target genes were obtained and found to be significantly associated with pathways in cancer; among these genes, MAPKs and PP1/2 phosphatases were defined as the hub genes of cantharidin in HCC. This result is consistent with the previously reported targets of cantharidin. In addition, 100 CTD- associated and EMT-related genes were obtained, suggesting that CTD may inhibit invasion and metastasis by regulating the expression of these genes in HCC. Additionally, we innovatively analysed the effect of CTD on histone modification. Interestingly, we found that the DEGs related to cantharidin were positively associated with H3k27me3 modification. Moreover, this H3K27me3-enriched gene set was involved in cell cycle pathways. We proposed that CTD likely inhibits tumour progression by regulating the cell cycle pathway through the EZH2-H3K27me3-dependent gene expression network.

Cantharidin was also confirmed to play an important role in immune enhancement. CTD is involved in miR-214 modulated macrophage polarization to exert antitumour effects on HCC [33]. Moreover, norcantharidin has functions of the immune enhancement, suppression of platelet aggregation and inhibition of renal interstitial fibrosis [34, 35]. Our results indicated that chemokine biosynthetic and metabolic pathways are positively associated with cantharidin treatment. Most of the differentially expressed chemokines and chemokine receptors were significantly positively correlated with the infiltration of immune cells, especially CD4 + T cells, Tfh cells, NK cells, NKT cells, Tregs and macrophages. Consistent with the analysis results, the results of animal experiments indicated that the proportions of CD4+/CD8 + T and B cells were increased, but the proportion of Tregs was decreased after treatment with CTD.

The EZH2-related pathway has been reported to be involved in the regulation of various immune cells including macrophages [36]. EZH2 inhibitors suppress EZH2-mediated H3K27me3 levels and regulate macrophages by skewing the polarization of M2 towards effector M1 macrophages in CRC. EZH2 inhibits NK cell-mediated antitumour immunity by suppressing CXCL10 expression in an HDAC10-dependent manner [37]. It can decrease antigen-specific CD8 + T-cell proliferation, and IFNγ production to enhance antigen presentation and thus antitumour immunity in head and neck cancer [38]. Moreover, we found that EZH2 expression was significantly associated with that of several chemokines and chemokine receptors in HCC. Taken together, these findings indicate that CTD plays a critical role in antitumour immunity by regulating chemokine or EZH2 related pathways.

Recently, the therapeutic application of monoclonal antibodies targeting inhibitory pathways such as PD-1 and PD-L1 has been confirmed to generate meaningful improvement in the clinical outcome of HCC [39]. The combination of PD-L1 antibody (atezolizumab) with Avastin (bevacizumab) against vascular endothelial growth factor (VEGF) has been approved for clinical treatment of patients with advanced HCC [40, 41]. In this study, we firstly found that the PD­1/PD-L1 is dramatically repressed by CTD. Combined with the results that CTD was involve in chemokine, inflammatory factor expression, and immune cell proportion regulation. We speculated that CTD maybe regulated immune response pathway to inhibit immune cells infiltration and promote anti-tumor immune activation in HCC.


In this study, we have not only identified the reported cantharidin targets MAPK and PPP1/2 phosphatase, but also confirmed several new targets of CTD in liver cancer. We revealed that MAPK, PPP1/2 phosphatase and EMT-related genes act as the hub genes of CTD network to regulate apoptosis and EMT processes. Moreover, CTD may represent a potent anticancer agent in HCC cells to regulated cell cycle via EZH2-H3K27me3 dependent genes expression network. In addition, we also confirm that CTD is involved in immune response, including the regulation of the chemokine related genes expression, inflammatory cytokines and immune checkpoint genes to repress tumor processes (Fig. 8). Our results provide a systematic view of the potential anticancer mechanism of cantharidin in HCC. Moreover, it indicates the potential research direction for innovative immunotherapy strategies in HCC. This will provide theoretical reference for the promotion of traditional Chinese medicine in clinical treatment for liver cancer.

Fig. 8
figure 8

The function of cantharidin in HCC. Cantharidin is involved in regulation the cell apoptosis, EMT progresses, EZH2/H3K27me3 related cell cycle pathway and immune response to exert antitumor function in HCC.

Data Availability

The datasets used in this article are publicly available as described in Materials and Methods. All result data was provided in the manuscript. All the gene expression raw data was provided in supplementary material. If anyone needs, they also can obtain raw data by contacting with the corresponding author.


  1. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021; 134:783–791. doi:

    Article  PubMed  Google Scholar 

  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71:209–49. doi:

    Article  PubMed  Google Scholar 

  3. Kulik L and El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019; 156:477–491.e471.

    Article  PubMed  Google Scholar 

  4. Xi SY and Minuk GY. Role of traditional chinese medicine in the management of patients with hepatocellular carcinoma. World J Hepatol. 2018; 10(11):799–806. doi:

    Article  PubMed  PubMed Central  Google Scholar 

  5. Zhang LY, Zhang JG, Yang X, Cai MH, Zhang CW, Hu ZM. Targeting Tumor Immunosuppressive Microenvironment for the Prevention of hepatic Cancer: applications of Traditional Chinese Medicines in targeted delivery. Curr Top Med Chem. 2020; 20(30):2789–2800. doi:

    Article  CAS  PubMed  Google Scholar 

  6. Yang M, Zhu SJ, Shen C, Zhai R, Li DD, Fang M, et al Clinical Application of Chinese Herbal Injection for Cancer Care: Evidence-Mapping of the Systematic Reviews, Meta-analyses, and Randomized Controlled Trials. Front Pharmacol. 2021; 12:666368. doi: eCollection 2021.

  7. Yang M, Zhu SJ, Shen C, Zhang Y, Jiang HL, Bao YD, et al Chinese patent medicine Aidi injection for cancer care: an overview of systematic reviews and meta-analyses. J Ethnopharmacol. 2022; 282:114656. doi: Epub 2021 Sep 20.

    Article  CAS  PubMed  Google Scholar 

  8. An P, Lu D, Zhang LJ, Lan HY, Yang HX, Ge GB, et al Synergistic antitumor effects of compound-composed optimal formula from Aidi injection on hepatocellular carcinoma and colorectal cancer. Phytomedicine. 2022; 103:154231. Epub 2022 Jun 2.

  9. Guo S, Li Y, Su H, Meng MY, Xi JX, Mo GY, et al Aidi injection as adjunctive treatment to gemcitabine-based chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. Pharm Biol. 2021; 59(1):1260–1275. doi:

    Article  CAS  PubMed  Google Scholar 

  10. Wang H, Wu Z, Liu Y, Wang MM, Stalin A, Guo SY, et al A novel strategy to reveal clinical advantages and molecular mechanism of aidi injection in the treatment of pancreatic cancer based on network meta-analysis and network pharmacology. J Ethnopharmacol. 2022; 285:114852. doi: Epub 2021 Nov 24.

    Article  CAS  PubMed  Google Scholar 

  11. Naz F, Wu Y, Zhang N, Z, Yu CY. Anticancer attributes of Cantharidin: involved Molecular Mechanisms and Pathways. Molecules. 2020; 25(14):3279. doi:

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Zhu M, Shi X, Gong Z, Su Q, Yu RZ, Wang B et al Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner. Pharmacol Res. 2020; 158:104868. doi: Epub 2020 May 12.

    Article  CAS  PubMed  Google Scholar 

  13. Song M, Wang X, Luo Y, Liu ZL, Tan W, Ye PC, et al Cantharidin suppresses gastric cancer cell migration/invasion by inhibiting the PI3K/Akt signaling pathway via CCAT1. Chem Biol Interact. 2020; 317:108939. doi: Epub 2020 Jan 13.

    Article  CAS  PubMed  Google Scholar 

  14. Feng IC, Hsieh MJ, Chen PN, Hsieh YH, Ho HY, Shun-Fa Yang SF, et al Cantharidic acid induces apoptosis through the p38 MAPK signaling pathway in human hepatocellular carcinoma. Environ Toxicol. 2018; 33(3):261–268. doi: Epub 2017 Nov 21.

    Article  CAS  PubMed  Google Scholar 

  15. Zhou H, Xu J, Wang S, Peng JF. Role of cantharidin in the activation of IKKα/IκBα/NF–κB pathway by inhibiting PP2A activity in cholangiocarcinoma cell lines. Mol Medicine Report. 2018; 17(6):7672–7682. doi: Epub 2018 Apr 5.

  16. Wei C, Deng X, Gao S, Wan XM, Chen J. Cantharidin Inhibits Proliferation of Liver Cancer by Inducing DNA Damage via KDM4A-Dependent Histone H3K36 Demethylation. Evid Based Complement Alternat Med. 2022; 2022:2197071. doi:

  17. Xia J, Li J, Tian L, Ren XD, Liu C, Liang CY. Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects. J Med Chem. 2022; 2022:2197071. doi:

  18. Sanna L, Marchesi I, Melone MAB, Bagella L. The role of enhancer of zeste homolog 2: from viral epigenetics to the carcinogenesis of hepatocellular carcinoma. J Cell Physiol. 2018; 233(9):6508–6517. doi: Epub 2018 Mar 25.

    Article  CAS  PubMed  Google Scholar 

  19. Wu SY, Xie ZY, Yan LY, Liu XF, Zhang Y, Wang DA, et al The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma. BMC Immunol. 2022; 23(1):28. doi:

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Yu L, Shen HJ, Ren XH, Wang AQ, Zhu S, Zheng YF, et al Multi-omics analysis reveals the interaction between the complement system and the coagulation cascade in the development of endometriosis. Sci Rep. 2021; 11(1): 11926. doi:

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Wu DJ, Yin ZH, Ji YS, Li, Li YX, Meng FQ, et al Identification of novel autophagy-related lncRNAs associated with a poor prognosis of colon adenocarcinoma through bioinformatics analysis. Sci Rep. 2021; 11(1):8069. doi:

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Kanehisa M and Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000; 28(1):27–30. doi:

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023; 51(D1): D587-D592. doi:

    Article  PubMed  Google Scholar 

  24. Liu YQ, Wang JW, Li L, Qin HB, Wei Y, Zhang X, et al AC010973.2 promotes cell proliferation and is one of six stemness-related genes that predict overall survival of renal clear cell carcinoma. Sci Rep. 2022; 12(1):4272. doi:

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Zhang D, Xu XC, Wei Y, Chen XL, Li GY, Lu ZW, et al Prognostic role of DNA damage response genes mutations and their association with the sensitivity of olaparib in prostate Cancer patients. Cancer Control. 2022; 29:10732748221129451. doi:

    Article  PubMed  PubMed Central  Google Scholar 

  26. Zhou J, Ren Y, Tan L, Song XMT, Wang M, Li YZ, et al Norcantharidin: research advances in pharmaceutical activities and derivatives in recent years. Biomed Pharmacother. 2020; 131:110755. doi: Epub 2020 Sep 25.

    Article  CAS  PubMed  Google Scholar 

  27. Sun S, Shang E, Ju AX, Li YL, Qian Wu Q, Li QH, et al Tumor-targeted hyaluronic acid-mPEG modified nanostructured lipid carriers for cantharidin delivery: an in vivo and in vitro study. Fitoterapia. 2021; 155:105033. doi: Epub 2021 Sep 11.

    Article  CAS  PubMed  Google Scholar 

  28. Xie MH, Fu ZL, Hua AL, et al A new core-shell-type nanoparticle loaded with paclitaxel/norcantharidin and modified with APRPG enhances anti-tumor effects in hepatocellular carcinoma. Front Oncol. 2022; 12:932156. doi: eCollection 2022.

  29. Liu F, Zhu XT, Li Y, Zhou JF, Chen Q, Li JB, et al Magnesium demethylcantharidate inhibits hepatocellular carcinoma cell invasion and metastasis via activation transcription factor FOXO1. Eur J Pharmacol. 2021; 911:174558. doi: Epub 2021 Oct 8.

    Article  CAS  PubMed  Google Scholar 

  30. Huang X, Xie W, Yu X, Fan C, Fan CY, Wang J, Cao Y, et al Methyl-Cantharidimide Inhibits Growth of Human Hepatocellular Carcinoma Cells by Inducing Cell Cycle Arrest and Promoting Apoptosis. Front Oncol. 2019; 9:1234. doi: eCollection 2019.

  31. Sun CY, Zhu Y, Li XF, Tang LP, Su ZQ, Wang XQ, et al Norcantharidin alone or in combination with crizotinib induces autophagic cell death in hepatocellular carcinoma by repressing c-Met-mTOR signaling. Oncotarget. 2017; 8(70):114945–114955. doi: eCollection 2017 Dec 29.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Li YD, Mao Y, Dong XD, Lei ZN, Yang YQ, Lin LZ, et al Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells. Front Oncol. 2020; 10:932. doi: eCollection 2020.

  33. Lu S, Gao Y, Huang XL, Wang LH. Cantharidin exerts anti-hepatocellular carcinoma by miR-214 modulating macrophage polarization. Int J Biol Sci. 2014; 10(4):415 – 25. doi: eCollection 2014.

  34. Mo LJ, Zhang XJ, Shi XJ, Wei LL, Zhang DP, Li HW, et al Norcantharidin enhances antitumor immunity of GM-CSF prostate cancer cells vaccine by inducing apoptosis of regulatory T cells. Cancer Sci. 2018; 109 (7):2109–2118. doi: Epub 2018 Jun 21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Xu LL, Su BJ, Mo LJ, Zhao CY, Zhao ZL, Li HW, Hu ZM, et al Norcantharidin induces immunogenic cell death of bladder Cancer cells through promoting autophagy in Acidic Culture. Int J Mol Sci. 2022; 23(7):3944. doi:

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Li C, Song JG, Guo ZY, Gong YQ, Zhang TR, Huang JQ, et al EZH2 Inhibitors Suppress Colorectal Cancer by Regulating Macrophage Polarization in the Tumor Microenvironment. Front Immunol. 2022; 13: 857808. doi: eCollection 2022.

  37. Zhou L, Mudianto T, Ma X, Riley R, Uppaluri R. Targeting EZH2 enhances Antigen Presentation, Antitumor Immunity, and circumvents Anti-PD-1 resistance in Head and Neck Cancer. Clin Cancer Res. 2020; 26(1):290–300. doi: Epub 2019 Sep 27.

    Article  CAS  PubMed  Google Scholar 

  38. Bugide S, Gupta R, Green MR, Wajapeyee N. EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner. Proc Natl Acad Sci USA. 2021;118(30): e2102718118. doi:

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Khanam A, Kottilil S. New therapeutics for HCC: does Tumor Immune Microenvironment Matter? Int J Mol Sci. 2022; 24(1):437. doi:

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Li Q, Han JJ, Yang YL, Chen Y. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol. 2022; 13:1070961. doi: eCollection 2022.

  41. Sperandio RC, Pestana RC, Miyamura BV, Kaseb AO. Hepatocellular Carcinoma Immunotherapy. Annu Rev Med. 2022; 73:267–278. doi: Epub 2021 Oct 4.

    Article  CAS  PubMed  Google Scholar 

Download references




This work was supported by Natural Science Foundation of Inner Mongolia (2020MS08132), Science and Technology Major Project of Inner Mongolia (KCBJ2018021), The Technology Plan Project of Inner Mongolia (2021GG0168), The Development for Young Scientific and Technological Talents in Colleges of Inner Mongolia (NMGIRT2228), Health Science and Technology Program of Inner Mongolia (202201222).

Author information

Authors and Affiliations



Hai sheng Wang designed the project. Jia Yan wrote the manuscript. Xiu ling Deng, Shi qi Ma and Yu hui Li completed all experiments. Gui tao Shi revised the manuscript. All data analysis was performed by Jia Yan and Yu min Gao. Hai sheng Wang provided reagents and participated in the preparation of the manuscript. All authors provided critical feedback on the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Gui tao Shi or Hai sheng Wang.

Ethics declarations

Ethics approval and consent to participate

All experiments were approved by Inner Mongolia medical university Animal Care and Use Committee and authorized by the Ethics Committee of Inner Mongolia medical university (YKD202102034), all experiments were performed in accordance with relevant guidelines and regulations. All methods are reported in accordance with ARRIVE guidelines for the reporting of animal experiments.

Consent for publication

Not applicable.

Competing interests

The authors declared that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Additional File 1

: All differently expressed genes in HepG2 cell after cantharidin treatment

Additional File 2

: Figure S1 The chemical structure of cantharidin

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yan, J., Deng, X.l., Ma, S.q. et al. Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response. BMC Complement Med Ther 23, 160 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Cantharidin
  • Hepatocellular carcinoma
  • Network pharmacology
  • H3K27me3
  • Immune response